| Dr James Vincent Castranova, MD | |
|
26 East Hobart Ave, Beach Haven Crest, NJ 08008-3529 | |
| (609) 494-6017 | |
| Not Available |
| Full Name | Dr James Vincent Castranova |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 26 East Hobart Ave, Beach Haven Crest, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407016603 | NPI | - | NPPES |
| 28947384I | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | MA21079 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Vincent Castranova, MD 26 East Hobart Ave, Beach Haven Crest, NJ 08008-3529 Ph: (609) 494-6017 | Dr James Vincent Castranova, MD 26 East Hobart Ave, Beach Haven Crest, NJ 08008-3529 Ph: (609) 494-6017 |
News Archive
The lack of progress in reducing children's exposures to pesticides, despite passage in 1996 of the Food Quality Protection Act (FQPA), will be highlighted during a symposium organized by The Organic Center on Sunday, February 19th at the 2006 annual meeting of the American Association for the Advancement of Science (AAAS).
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.
MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.
Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany.
› Verified 2 days ago